KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Invested Capital (2016 - 2025)

Historic Return on Invested Capital for Halozyme Therapeutics (HALO) over the last 10 years, with Q4 2025 value amounting to 0.15%.

  • Halozyme Therapeutics' Return on Invested Capital fell 800.0% to 0.15% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.15%, marking a year-over-year decrease of 800.0%. This contributed to the annual value of 0.16% for FY2025, which is 1000.0% down from last year.
  • Per Halozyme Therapeutics' latest filing, its Return on Invested Capital stood at 0.15% for Q4 2025, which was down 800.0% from 0.31% recorded in Q3 2025.
  • Halozyme Therapeutics' 5-year Return on Invested Capital high stood at 0.46% for Q3 2021, and its period low was 0.12% during Q1 2023.
  • In the last 5 years, Halozyme Therapeutics' Return on Invested Capital had a median value of 0.22% in 2024 and averaged 0.25%.
  • Its Return on Invested Capital has fluctuated over the past 5 years, first surged by 5500bps in 2021, then plummeted by -3200bps in 2023.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Return on Invested Capital stood at 0.44% in 2021, then crashed by -70bps to 0.13% in 2022, then rose by 24bps to 0.16% in 2023, then soared by 40bps to 0.23% in 2024, then tumbled by -34bps to 0.15% in 2025.
  • Its Return on Invested Capital was 0.15% in Q4 2025, compared to 0.31% in Q3 2025 and 0.29% in Q2 2025.